End Results Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

U S FDA ACKNOWLEDGES ASTELLAS RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesUnited kingdomMoitreyee chatterjee kishoreNaoki okamuraRare diseases information centerTranslational sciencesAmerican cancer societyJapan ministry of healthNational institutes of health centerPrnewswire astellas pharma incNational cancer instituteAmerican society of clinical oncologyEnd results programDrug administrationOncology developmentAstellas pharma inc

Exploiting the Vulnerabilities of High-Grade Serous Ovarian Cancer Through WEE1 Inhibition

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.

United statesDana farber cancer instituteSri lankaJoycef liuEnd results programZentalis pharmaceuticalsWomen healthHarvard medical schoolDivision of gynecologic oncologyAmerican society of clinical oncology annual meetingNational cancer institute surveillanceGynecologic oncologyDisplays preliminary efficacyClinical oncology annual meetingGynecologic oncology annual meetingCancer institute surveillance

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs
jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.

United statesJonathan kimmelmanSanofi pasteurRossy cancer network philip kuok graduate fellowshipOr foundationMcgill college aveAmylyx pharmaceuticalsEnd results programMcgill universityHealth sciencesSociety of clinical trialsCanada research chairs programDepartment of equityRossy cancer networkSelection criteriaOpen science framework

Truqap recommended for EU breast cancer approval | Company Announcement

Investegate announcements from Truqap recommended for EU breast cancer approval

United kingdomDaiichi sankyoAdrian kempAstrazeneca truqapMerck co incCommittee for medicinal products human useNational cancer instituteEnd results programInstitute of cancer researchEuropean medicines agencyWorld health organizationInvestor relations teamCancer research technologyEuropean unionNational comprehensive cancer networkZeneca truqap

ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of.

United kingdomIsrael generalDaiichi sankyoTrastuzumab deruxtecanCapecitabine monotherapyEnd results programMerck co incNational cancer instituteDaiichi sankyo incLow metastatic breast cancerSolid tumorsPositive locally advancedMetastatic gastric cancerPositive metastatic breastLow metastatic breastMutant unresectable